Efficacy
41% (95% CI, 24 to 59) of patients had a major haematologic response with a median response time of 2.9 weeks (range, 1.6 to 24), duration of 2 months to 14 months or more (median, 3 months) and the estimated rate of a sustained response of at least 12 months was 8%.r
47% had a major cytogenetic response with a median response time of 1 month (range, 0.9 to 3.7), median duration of 3.7 months and the estimated rate of a sustained response of at least 12 months was 32%. 38% had a complete cytogenetic response.r
The rate of progression-free survival at 12 months was estimated to be 7% (median, 3 months). The overall survival rate at 12 months was estimated to be 40% (median, 8 months).r
© New England Journal of Medicine 2013